Molecular detection of clonally rearranged cells in peripheral blood progenitor cell harvests from multiple myeloma patients
- 1 September 1994
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 88 (1) , 110-116
- https://doi.org/10.1111/j.1365-2141.1994.tb04985.x
Abstract
Summary. Peripheral blood progenitor cells (PBPC) are increasingly used for autologous reconstitution following high-dose chemotherapy in multiple myeloma but it is unclear whether these cells are less likely to be contaminated with malignant cells than bone marrow (BM). We have investigated this using immunoglobulin heavy-chain (IgH) gene fingerprinting, a polymerase chain reaction based technique with a sensitivity of 0.1–0.01% (10-3 - 10-4). We have looked for patient-specific IgH rearrangements in leukapheresis samples from eight myeloma patients undergoing PBPC harvest. Seven were in first remission (six partial, one complete) and one in second complete remission. Mobilization of PBPC was accomplished using cyclophosphamide (4 or 7 mg/m2) and rhG- or GM-CSF. Between two and five leukaphereses were performed in each patient. Patient-specific IgH rearrangements were identified in diagnostic BM in all patients and bands of identical size were found in one or more leukaphereses from 6/8 patients. Overall, 14/32 leukaphereses were shown to be contaminated. Two patients who showed contamination of at least one PBPC harvest had BM harvests in which contaminating cells were not detectable, suggesting that PBPC are not necessarily less likely to be contaminated than marrow stem cells. These results indicate that PBPC harvests from the majority of myeloma patients are likely to contain contaminating cells. Further studies are needed to determine whether these cells are clonogenic and whether they contribute to relapse.Keywords
This publication has 21 references indexed in Scilit:
- The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell.The Journal of Experimental Medicine, 1993
- Gene-marking to trace origin of relapse after autologous bone-marrow transplantationThe Lancet, 1993
- Extramedullary progression of multiple myeloma following GM‐CSF treatment — grounds for caution?European Journal of Haematology, 1992
- Analysis of tumor‐specific immunoglobulin gene rearrangement in peripheral blood B‐cells of multiple myeloma patientsAmerican Journal of Hematology, 1991
- Immunoglobulin gene ‘fingerprinting’: an approach to analysis of B lymphoid clonality in lymphoproliferative disordersBritish Journal of Haematology, 1991
- Detection of monoclonal B lymphocytes in bone marrow and peripheral blood of multiple myeloma patients by immunoglobulin gene rearrangement studiesBritish Journal of Haematology, 1989
- INTENSIVE TREATMENT OF MULTIPLE MYELOMA AND CRITERIA FOR COMPLETE REMISSIONThe Lancet, 1989
- Circulating monoclonal B lymphocytes in multiple myelomaBritish Journal of Haematology, 1989
- No detectable malignant B cells in the peripheral blood of patients with multiple myelomaBritish Journal of Haematology, 1989
- Molecular diagnosis of haematological disorders using DNA from stored bone marrow slidesBritish Journal of Haematology, 1987